in vivo News and Research

RSS

Read-through molecule improves muscle function in DMD

A compound that results in a read-through on nonsense mutations in messenger RNA restores dystrophin expression in an animal model of Duchenne muscular dystrophy, research shows.

9 Jul 2012

Next generation predictive 3D cell toxicity assays to be developed by Medicyte GmbH and Reinnervate Ltd

Two market leading companies in the field of cell based assays and predictive toxicology today announced a new product collaboration. Medicyte (inventors of the upcyte® technology) and Reinnervate (market leaders in the growing field of 3D cell culture) said they will work together to combine their upcyte® and Alvetex®Scaffold technologies to bring next generation cell bases assays to the biopharma and academic research markets.

9 Jul 2012

Bioengineers develop microfluidic platform to mechanically confine cancer cells

It's well known in conventional biology that during the process of mammalian cell division, or mitosis, a mother cell divides equally into two daughter cells. But when it comes to cancer, say UCLA researchers, mother cells may be far more prolific.

6 Jul 2012

Researchers to use nanoscopic clay for controlled release of drugs in patients

University of Granada and the Spanish Consejo Superior de Investigaciones Cient-ficas (CSIC) researchers will use nanoscopic clay for the controlled release of drugs in patients, with the aim of designing more efficient and less toxic drugs. This is a pilot research study that includes CSIC and University of Granada researchers and researchers from other institutions.

6 Jul 2012

Insight into understanding IDH mediated disease

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in cancer metabolism, announced today the publication of a new study that provides further evidence of the link between a mutated metabolic enzyme and acute myeloid leukemia (AML), one of the most common types of leukemia in adults.

6 Jul 2012

Treating Sickle Cell Disease with L-Glutamine

By focusing on how best to help patients, researchers can sometimes find solutions that are much simpler than anticipated. That has been the guiding approach to our efforts to develop a treatment for sickle cell disease.

3 Jul 2012

Quality solutions for inhaler testing: new edition published by Copley

The new version of ‘Quality Solutions for Inhaler Testing’ from Copley Scientific not only showcases the latest developments in inhaled product testing equipment but also provides practical guidance on achieving robust and reliable measurement and analysis.

3 Jul 2012

Scientists discover Eya1 enzyme control of pulmonary barrier integrity

Scientists have provided the first evidence that an enzyme called Eya1 protein phosphatase is a critical regulator of lung function and that this may have broad implications for sufferers of a variety of pulmonary diseases.

3 Jul 2012

Researchers identify genes that influence degeneration of the hippocampus

In a genome-wide association (GWA) study, researchers from Boston University Schools of Medicine (BUSM) and Public Health (BUSPH) have identified several genes which influence degeneration of the hippocampus, the part of the brain most associated with Alzheimer disease (AD).

29 Jun 2012

Magnet guides iron-loaded cells to specific damaged sites in the heart

Optimal stem cell therapy delivery to damaged areas of the heart after myocardial infarction has been hampered by inefficient homing of cells to the damaged site. However, using rat models, researchers in France have used a magnet to guide cells loaded with iron oxide nanoparticles to key sites, enhancing the myocardial retention of intravascularly delivered endothelial progenitor cells.

27 Jun 2012

RXi Pharmaceuticals initiates RXI-109 Phase 1 trial to reduce surgical scars

RXi Pharmaceuticals Corporation today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

27 Jun 2012

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.

26 Jun 2012

KaloBios’ KB001 shows promise against Pa pneumonia

Phase 2a trial results with KB001 suggest the recombinant, human PEGylated monoclonal antibody fragment, under development by KaloBios Pharmaceuticals, Inc. and Sanofi Pasteur, offers potential as an alternative to antibiotics for preventing or reducing pneumonias in mechanically ventilated intensive care unit (ICU) patients heavily colonized with Pseudomonas aeruginosa (Pa).

26 Jun 2012

Teleflex announces acquisition of Semprus BioSciences

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.

25 Jun 2012

Cell-free, biodegradable artery graft improves coronary artery bypass surgeries

With the University of Pittsburgh's development of a cell-free, biodegradable artery graft comes a potentially transformative change in coronary artery bypass surgeries: Within 90 days after surgery, the patient will have a regenerated artery with no trace of synthetic graft materials left in the body.

25 Jun 2012

Study reveals previously unknown function of Thbd-aPC pathway in radiation mitigation

New research in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning.

25 Jun 2012

UC3M joins European research project on tuberculosis treatments

Scientists at the Carlos III University in Madrid (UC3M) are participating in a European research project designed to study tuberculosis treatments. The objective of the study is to improve diagnostic imaging technology in order to help develop new drugs to treat the disease.

22 Jun 2012

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

22 Jun 2012

Selenium reduces Staph populations in medical implants

Selenium is an inexpensive element that naturally belongs in the body. It is also known to combat bacteria. Still, it had not been tried as an antibiotic coating on a medical device material. In a new study, Brown University engineers report that when they used selenium nanoparticles to coat polycarbonate, the material of catheters and endotracheal tubes, the results were significant reductions in cultured populations of Staphylococcus aureus bacteria, sometimes by as much as 90 percent.

22 Jun 2012

FimH antagonists can effectively treat UTIs

A potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics is being reported in ACS' Journal of Medicinal Chemistry. It involves so-called FimH antagonists, which are non-antibiotic compounds and would not contribute to the growing problem of antibiotic resistance bacteria.

21 Jun 2012